Back to News
Market Impact: 0.2
FibroBiologics Secures European Patent For Fibroblast Therapeutic Technology; Stock Up
Source: Nasdaq
Healthcare & BiotechPatents & Intellectual Property
FibroBiologics received European Patent No. 3568465 from the European Patent Office for methods of enhancing fibroblast therapeutic activity. The patent strengthens intellectual-property protection for the clinical-stage biotech company's fibroblast therapeutic technology, though no financial or clinical-development impact was disclosed.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.35
Ticker Sentiment
FBLG0.70
More News
- Walgreens owner nears $9 billion deal to sell Boots chain- WSJ
- Eli Lilly says closely watched combo obesity regimen boosts weight loss in mid-stage trial
- Lilly’s Foundayo shows cardiovascular safety in diabetes trial
- Some Oura IPO Investors Were Said to Push Back Citing Valuation
- Nvidia is approaching a breakout level. Plus, what we want to see from Micron
- Wall Street is closing out a strong quarter. Plus, Lilly's mixed obesity drug trial data